Penumbra, Inc. (FRA:0P8)
Germany · Delayed Price · Currency is EUR | Market Cap | 10.91B +29.3% |
| Revenue (ttm) | 1.32B +17.6% |
| Net Income | 140.56M +8.7% |
| EPS | 3.56 +8.8% |
| Shares Out | n/a |
| PE Ratio | 77.61 |
| Forward PE | 57.20 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 276.80 |
| Previous Close | 277.40 |
| Day's Range | 276.20 - 277.60 |
| 52-Week Range | 193.10 - 306.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 2, 2026 |
About Penumbra
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron ... [Read more]
Financial Performance
In 2025, Penumbra's revenue was $1.40 billion, an increase of 17.50% compared to the previous year's $1.19 billion. Earnings were $177.69 million, an increase of 1168.11%.
Financial numbers in USD Financial StatementsNews
Incuvate files patent infringement lawsuit against Penumbra
Incuvate announced that it has filed a patent-infringement lawsuit against Penumbra (PEN), Inc. in the U.S. District Court for the Northern District of California. “The lawsuit, filed August 19, 2026,...
Penumbra reports Q2 EPS 88c, consensus $1.18
Reports Q2 revenue $390M, consensus $390.08M. Given the pending acquisition of Penumbra (PEN) by Boston Scientific (BSX), the company will not be providing financial guidance for the full year 2026…
Penumbra, Inc. Reports Second Quarter 2026 Financial Results
ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.
Penumbra Earnings release: Q2 2026
Penumbra released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Penumbra Quarterly report: Q2 2026
Penumbra has published its Q2 2026 quarterly earnings report on July 30, 2026.
Penumbra says THUNDER study met predefined performance goal
Penumbra (PEN) announced the results of THUNDER, an Investigational Device Exemption study, to evaluate the safety and effectiveness of THUNDERBOLT, the company’s novel computer assisted vacuum thromb...
THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care
First and only CAVT device for stroke demonstrated high revascularization rates, short procedure times and low complication rates ALAMEDA, Calif., July 22, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: P...
Penumbra announces the initiation of its FORWARD study
Penumbra (PEN) announced the initiation of its FORWARD study, an international, real world prospective, multi-center study. The study will collect safety and efficacy data on mechanical thrombectomy, ...
First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke
ALAMEDA, Calif., July 7, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the initiation of its FORWARD study, an international, real world prospect...
Penumbra price target lowered to $320 from $335 at Evercore ISI
Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Penumbra (PEN) to $320 from $335 and keeps an Outperform rating on the shares. The firm’s Q2 preview for…
Penumbra secured CE Mark in Europe for Thunderbolt
Penumbra (PEN) announced it has secured CE Mark in Europe for Thunderbolt, further laying the groundwork for launching computer assisted vacuum thrombectomy technology to address acute ischemic stroke...
Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT
The THUNDERBOLT TM Computer Assisted Vacuum Thrombectomy (CAVT TM) technology introduces modulated aspiration for acute ischemic stroke for the first time, enabling more rapid, complete clot removal ...
Penumbra receives FDA clearance for Thunderbolt
Penumbra (PEN) announced it has received U.S. FDA clearance for Thunderbolt, expanding its computer assisted vacuum thrombectomy technology to address acute ischemic stroke. Powered by the Penumbra En...
Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke
THUNDERBOLT is the first CAVT platform to deliver modulated aspiration for acute ischemic stroke — enabling faster, more complete clot removal ALAMEDA, Calif., June 11, 2026 /PRNewswire/ -- Penumbra, ...
Penumbra price target lowered to $335 from $345 at Evercore ISI
Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Penumbra (PEN) to $335 from $345 and keeps an Outperform rating on the shares.
Penumbra price target lowered to $350 from $374 at Citi
Citi lowered the firm’s price target on Penumbra (PEN) to $350 from $374 and keeps a Neutral rating on the shares.
Penumbra reports Q1 EPS 82c, consensus $1.06
Reports Q1 revenue $374.8M, consensus $372.04M.
Penumbra, Inc. Reports First Quarter 2026 Financial Results
ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026.
Penumbra Earnings release: Q1 2026
Penumbra released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Penumbra Quarterly report: Q1 2026
Penumbra has published its Q1 2026 quarterly earnings report on May 6, 2026.
Penumbra Proxy statement: Proxy filing
Penumbra filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Penumbra Proxy statement: Proxy filing
Penumbra filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Penumbra announces 90-day results of STORM-PE randomized controlled trial
Penumbra (PEN) announced 90-day results of the landmark STORM-PE randomized controlled trial, which found that patients with acute intermediate-high risk pulmonary embolism who were treated with compu...
New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients
ALAMEDA, Calif., April 13, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced 90-day results of the landmark STORM-PE randomized controlled trial (RCT), which found that patients with acute int...